Return to results
Journal articles (2011), Graefe's Archive for Clinical and Experimental Ophthalmology, 249 (4), pp. 521-527

Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study

COHEN S.-Y., SOUIED E.H., WEBER André Paul, DUPEYRON G., PUYOU de POUVOURVILLE Gérard , LIEVRE M.

Age-related macular degeneration is the primary cause of blindness in developed countries. Current treatments of this degenerative disease mainly include laser, photodynamic therapy with verteporfin and administration of anti-vascular endothelial growth factors. The LUEUR (LUcentis® En Utilisation Réelle) study is composed of a cross-sectional part (LUEUR1), which examined the current management of wet AMD in France, and a follow-up part (LUEUR2), which will assess the development of patients treated for wet AMD over 4 years. Here we describe the results of LUEUR1. Patients with wet AMD were enrolled during a routine medical examination in LUEUR1, a cross-sectional, observational, prospective, multicentre study. Investigators recorded patient demographics, visual acuity, characteristics of wet AMD lesions, date of AMD diagnosis, comorbidities, previous treatments, treatments prescribed at inclusion, and low vision rehabilitation. A total of 72 investigators recruited 1,019 patients with wet AMD, corresponding to 1,405 eyes affected by the disease. The mean age of patients was 78.7 ± 7.3 years. Most were female (62.3%) and non-smokers (66.9%). The mean visual acuity was 49.12 ± 24.18 Early Treatment Diabetic Retinopathy Study letters. Most eyes showed occult (52.8%) and subfoveal (84.6%) choroidal neovascularisation. Bilateral wet AMD affected 37.9% of patients. The median time since diagnosis was 12 months. Ranibizumab-based therapy (67.3%) and photodynamic therapy (29.8%) were the most frequent previous treatments. Prior to inclusion, 5.6% of patients had low vision rehabilitation. When a treatment was prescribed on the day of inclusion, it was most often ranibizumab (89.0% of all treatments at inclusion). The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy. Link to the article

COHEN, S.Y., SOUIED, E.H., WEBER, A.P., DUPEYRON, G., PUYOU DE POUVOURVILLE, G. and LIEVRE, M. (2011). Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study. Graefe's Archive for Clinical and Experimental Ophthalmology, 249(4), pp. 521-527.